FindMyKOL
Clinical trialNCT07355335Not, yet, recruitingPhase 1Interventional

Ziftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AML

SponsorMassachusetts General HospitalEnrollment24KMT2A-rearrangedNPM1-mutant Refractory or Relapsed AML
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the safety and tolerability of mezigdomide in combination with ziftomenib in adolescent and adult participants with either KMT2A-rearranged (KMT2A-r) or NPM1-mutant relapsed or refractory acute myeloid leukemia (AML).
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

2 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Dana-Farber Cancer Institute

    Boston, Massachusetts, United States

    Richard Stone, MD
  • Massachusetts General Hospital

    Boston, Massachusetts, United States

    Amir Fathi, MD

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

MezigdomideZiftomenib
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 Jul 2026
Primary completion
1 Jul 2027
Completion
1 Jan 2028
Last update posted
22 Jan 2026
Registered enrollment
24
Registry id
NCT07355335
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.